Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study
Table 1
Sociodemographic and clinical data at baseline in patients with postacute sequelae of SARS-CoV-2 (N = 10).
n (%), unless otherwise stated
Sociodemographic data
Sex
Men
5 (50)
Women
5 (50)
Age
Mean (min-max)
50.3 (29–63)
Marital status
Single/widow/divorced
3 (30)
Married/partner, not living together
7 (70)
Cardiovascular risk factors
Smoking habit
Nonsmoker
6 (60)
Ex-smoker
4 (40)
Body mass index (kg/m2)
≥25
9 (90)
Exact value, mean (Sd)
28.6 (3.6)
Diabetes mellitus
0
Hypertension
1 (10)
Hyperlipidemia
1 (10)
Myocardial infarction
0
Other co-morbidities
Fibromyalgia syndrome
1 (10)
Polyarthritis
1 (10)
Polymyalgia rheumatic
0
Prior anxiety/depression
4 (40)
Pulmonary disease
0
Clinical data
Systolic blood pressure (mmHg)
Mean (Sd)
127 (8.1)
Diastolic blood pressure (mmHg)
Mean, (Sd)
78 (6.8)
Heart rate (bpm)
Mean (Sd)
69 (13.7)
Ejection fraction
≥50%
10 (100)
NT-proBNP (ng/L)
Mean (Sd)
71.5 (50.81)
Pharmacologic treatments
Angiotensin-converting-enzyme-inhibitors
1 (10)
Angiotensin receptor blockers
1 (10)
Anticoagulants
0
Antidepressant
3 (30)
Antiplatelet agents
1 (10)
Asthma inhalers
Short-acting
6 (40)
Long-acting
0
Both
0
Beta blockers
5 (50)
Calcium channel blockers
6 (60)
If-inhibitor
1 (10)
Lipid-lowering agents
3 (30)
Long-acting nitrates
3 (30)
NT-proBNP, N-terminal of the prohormone brain natriuretic peptide.